GlassScriptPhysician profile
Adeoye A Aremu
NPI 1932415775
$2,559.51
in general payments reported to CMS, 2019-2025
22 companies · $452 in 2025
The $452 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $136 · 2021: $100 · 2022: $431 · 2023: $728 · 2024: $581 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,640 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,640.42 |
| Education | $120.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $1,049.78 | 2021-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $205.77 | 2022-2025 | Gvoke Hypopen |
| Abbott Laboratories | $196.19 | 2021-2025 | Freestyle Libre |
| Amgen INC. | $145.04 | 2019-2025 | Tepezza, Prolia, Evenity |
| Pfizer INC. | $133.00 | 2019-2025 | |
| Astellas Pharma US INC | $99.99 | 2025 | |
| Novo Nordisk INC | $81.35 | 2025 | Wegovy, Ozempic |
| Glaxosmithkline, LLC. | $79.98 | 2019-2020 | |
| Lundbeck LLC | $70.38 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $69.48 | 2022-2023 | Jardiance, Mounjaro |
| Ardelyx, INC. | $65.49 | 2024 | Ibsrela |
| Abbvie INC. | $59.87 | 2022-2024 | Qulipta, Ubrelvy |
| Phathom Pharmaceuticals, INC. | $48.42 | 2024-2025 | Voquezna |
| Allergan, INC. | $40.02 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $39.12 | 2019-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.29 | 2020-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $35.91 | 2025 | Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $27.85 | 2019-2022 | |
| Inogen, INC. | $20.37 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.22 | 2024 | |
| Kyowa Kirin, INC. | $18.43 | 2024 | Crysvita |
| Otsuka America Pharmaceutical, INC. | $16.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adeoye Aremu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.